Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Employees

122

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-14	HK$2.985	+0.51%	250,000
26-10-14	HK$2.970	+1.19%	858,100
26-10-13	HK$2.935	-3.93%	805,500
26-10-12	HK$3.055	-4.23%	883,000
26-10-09	HK$3.190	-3.63%	1,539,500

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.534CNY

Average target price

4.150CNY

Spread / Average Target

+63.75%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Antengene Corporation Limited

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Antengene Corporation Limited

Company calendar

Delayed Hong Kong S.E. 23:59:41 2026-10-14 EDT			5-day change	1st Jan Change
2.985 ^HKD	+0.51%		-9.82%	-21.24%

10-08	Antengene Corporation Limited Announces Presentation Of Latest Preclinical Results Of ATG-207 At ACR 2026	CI
09-20	Antengene Corporation Limited Doses First Patient in Pivotal Phase III CLINCH-3 Study of ATG-022	CI

Market Cap	1.74B 2.04B 260M 234M 218M 198M 371M 24.76B 374M 2.62B 1.02B 12.85B 977M 956M 41.33B	P/E 2026 *	4.78x	P/E 2027 *	-19.5x
Enterprise Value	1.74B 2.04B 260M 234M 218M 198M 371M 24.76B 374M 2.62B 1.02B 12.85B 977M 956M 41.33B	EV / Sales 2026 *	2.1x	EV / Sales 2027 *	5.16x
Free-Float	62.9%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	6996	Delayed
Tradegate	722	Real-time
Börse Stuttgart	722	Delayed
Deutsche Boerse AG	722	Delayed

10-08	Antengene Corporation Limited Announces Presentation Of Latest Preclinical Results Of ATG-207 At ACR 2026	CI
09-20	Antengene Corporation Limited Doses First Patient in Pivotal Phase III CLINCH-3 Study of ATG-022	CI
08-25	Antengene Corporation Limited Receives HREC Approval In Australia For Phase I ATTRACT Study Of ATG-201 In B Cell-Related Autoimmune Diseases	CI
08-25	Antengene's Autoimmune Disease Drug Candidate Approved for Phase I Trial in Australia	MT
08-21	Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-19	Antengene Presents Key R&D Highlights Including Atg-022 Clinical Data, Antengager and Trigager Tce Platforms, and Atg-207 Bifunctional Fusion Protein	CI
07-31	Antengene's CFO Steps Down; Chief Business Officer Named	MT
07-31	Antengene Corporation Limited Announces Management Changes, Effective August 1, 2026	CI
07-31	Antengene Corporation Limited Announces Resignation of Donald Andrew Lung as Chief Financial Officer, Effective August 1, 2026	CI
07-28	Antengene Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026	CI
07-13	Antengene Receives $60 Million Milestone in UCB Licensing Deal	MT
07-10	Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target	MT
07-09	Antengene Corporation Limited commences an Equity Buyback Plan for 67,924,413 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2026.	CI

Antengene Corporation Limited Stock

Stocks

6996

KYG039571008

Biotechnology & Medical Research

Valuation: Antengene Corporation Limited

Chart: Antengene Corporation Limited

Latest news: Antengene Corporation Limited

Analysts' recommendations: Antengene Corporation Limited

Press Releases: Antengene Corporation Limited

Quotes and Performance

Price Extremes

Managers and Directors: Antengene Corporation Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

10-08	Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026	PR
10-02	Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026	PR
09-20	Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022	PR
09-14	Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy	PR
08-24	Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases	PR

1 day	+0.51%
1 week	-9.82%
Current month	-13.73%
1 month	-10.90%
3 months	-33.52%
6 months	-51.46%
Current year	-21.24%

1 week	2.88	3.35
1 month	2.88	3.66
Current year	2.76	6.28
1 year	2.76	6.28
3 years	0.5	8.16
5 years	0.5	13.06
10 years	0.5	22.5

Manager	Title	Age	Since
Jian Ming Mei CEO	Chief Executive Officer	60	2018-08-27
Bing Hou CTO	Chief Tech/Sci/R&D Officer	42	2026-05-19
Godfrey Guo CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jian Ming Mei CHM	Chairman	60	2018-08-27
Jing Qian BRD	Director/Board Member	51	2020-11-08
Rafael Fonseca BRD	Director/Board Member	59	2023-04-13

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/10/26	Jing Qian	Other	Director	200,000	0.0294%
9/10/26	Bing Hou	Other		2,000,000	0.2944%
9/10/26	Rafael Fonseca	Other	Director	200,000	0.0294%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANTENGENE CORPORATION LIMITED	+0.51%	-9.82%	-44.41%	+126.14%	260M
WUXI APPTEC CO., LTD.	-2.01%	-7.86%	+60.74%	+70.97%	68.92B
ARGENX SE	+3.84%	-11.02%	+8.59%	+57.43%	51.9B
LONZA GROUP AG	+3.35%	+1.42%	+11.85%	+40.01%	48.73B
IQVIA HOLDINGS INC.	+0.51%	+1.51%	+27.96%	+31.43%	43.13B
REVOLUTION MEDICINES, INC.	+2.70%	-3.66%	+307.41%	+547.01%	41.48B
BEONE MEDICINES AG	+0.69%	-3.44%	+9.52%	+96.59%	39.96B
CELLTRION, INC.	+0.06%	-2.02%	+11.25%	+43.27%	30.6B
WUXI BIOLOGICS (CAYMAN) INC.	-0.56%	-8.58%	+37.62%	+0.94%	26.01B
BIONTECH SE	-0.39%	-6.92%	-13.60%	-14.40%	22.27B
Average	+0.87%	-6.28%	+41.69%	+99.94%	37.33B
Weighted average by Cap.	+0.98%	-4.90%	+55.07%	+103.91%

	2026 *	2027 *
Net sales	830M 973M 124M 111M 104M 94.28M 177M 11.8B 178M 1.25B 487M 6.12B 465M 455M 19.69B	338M 396M 50.43M 45.34M 42.31M 38.35M 72M 4.8B 72.44M 508M 198M 2.49B 189M 185M 8.01B
Net income	333M 391M 49.76M 44.74M 41.75M 37.84M 71.04M 4.74B 71.48M 501M 196M 2.46B 187M 183M 7.9B	-84.79M -99.36M -12.66M -11.38M -10.62M -9.63M -18.08M -1.2B -18.19M -127M -49.78M -625M -47.53M -46.5M -2.01B
Net Debt	-	-